- 4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
- 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
- 4DMT to Participate in Upcoming Investor Conference
- 4DMT Announces Presentations at ARVO 2024 Annual Meeting
- 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
- 4DMT to Participate in Upcoming Investor Conferences
- 4DMT Reports Full Year 2023 Financial Results and Operational Highlights
- 4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
- 4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
- 4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
More ▼
Key statistics
On Friday, 4D Molecular Therapeutics Inc (FDMT:NSQ) closed at 23.97, -33.88% below its 52-week high of 36.25, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.00 |
---|---|
High | 25.61 |
Low | 23.85 |
Bid | 23.00 |
Offer | 26.60 |
Previous close | 24.64 |
Average volume | 482.73k |
---|---|
Shares outstanding | 51.70m |
Free float | 49.35m |
P/E (TTM) | -- |
Market cap | 1.24bn USD |
EPS (TTM) | -2.36 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:15 BST.
More ▼